169 related articles for article (PubMed ID: 21270668)
41. Preoperative prediction of unresectability in malignant pleural mesothelioma.
Burt BM; Lee HS; Raghuram AC; Strange C; Mason J; Strange T; Delgado J; Sugarbaker DJ
J Thorac Cardiovasc Surg; 2020 Jun; 159(6):2512-2520.e1. PubMed ID: 32087959
[TBL] [Abstract][Full Text] [Related]
42. Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
Otoshi T; Kataoka Y; Ikegaki S; Saito E; Matsumoto H; Kaku S; Shimada M; Hirabayashi M
PLoS One; 2017; 12(10):e0185850. PubMed ID: 28968445
[TBL] [Abstract][Full Text] [Related]
43. [Computed tomographic findings in diffuse malignant pleural mesothelioma].
Bohndorf K; Calavreszos A; Koschel G; Hüsselmann H; Hain E
Rofo; 1985 Sep; 143(3):279-84. PubMed ID: 2996064
[TBL] [Abstract][Full Text] [Related]
44. A case of pleural epithelioid sarcoma of proximal type presenting as malignant pleural mesothelioma.
Madsen GA; Rasmussen TR; Bærentzen S
J Thorac Oncol; 2013 Oct; 8(10):e89-90. PubMed ID: 24457248
[No Abstract] [Full Text] [Related]
45. [Follow- up of a pleural malignant mesothelioma].
Vanwijck R; Verschakelen JA; Baert AL
J Belge Radiol; 1992 Oct; 75(5):389-91. PubMed ID: 1487461
[TBL] [Abstract][Full Text] [Related]
46. Stage Ia malignant pleural mesothelioma: clinical course and appropriate diagnostic process.
Maeda R; Isowa N; Onuma H; Miura H; Touge H; Kawasaki Y
Gen Thorac Cardiovasc Surg; 2009 May; 57(5):264-8. PubMed ID: 19440826
[TBL] [Abstract][Full Text] [Related]
47. Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group.
Armato SG; Labby ZE; Coolen J; Klabatsa A; Feigen M; Persigehl T; Gill RR
Lung Cancer; 2013 Nov; 82(2):190-6. PubMed ID: 24018024
[TBL] [Abstract][Full Text] [Related]
48. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.
Bograd AJ; Suzuki K; Vertes E; Colovos C; Morales EA; Sadelain M; Adusumilli PS
Cancer Immunol Immunother; 2011 Nov; 60(11):1509-27. PubMed ID: 21913025
[TBL] [Abstract][Full Text] [Related]
49. Current trends in radiologic management of malignant pleural mesothelioma.
Gill RR; Gerbaudo VH; Sugarbaker DJ; Hatabu H
Semin Thorac Cardiovasc Surg; 2009; 21(2):111-20. PubMed ID: 19822282
[TBL] [Abstract][Full Text] [Related]
50. 18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma.
Subramaniam RM; Wilcox B; Aubry MC; Jett J; Peller PJ
J Med Imaging Radiat Oncol; 2009 Apr; 53(2):160-9; quiz 170. PubMed ID: 19527361
[TBL] [Abstract][Full Text] [Related]
51. CT of malignant pleural mesothelioma.
Mirvis S; Dutcher JP; Haney PJ; Whitley NO; Aisner J
AJR Am J Roentgenol; 1983 Apr; 140(4):665-70. PubMed ID: 6601367
[TBL] [Abstract][Full Text] [Related]
52. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
[TBL] [Abstract][Full Text] [Related]
53. Prognostic value of FDG PET imaging in malignant pleural mesothelioma.
Ng DC; Hain SF; O'Doherty MJ; Dussek J
J Nucl Med; 2000 Aug; 41(8):1443-4. PubMed ID: 10945542
[No Abstract] [Full Text] [Related]
54. Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.
Francis RJ; Segard T; Morandeau L; Lee YC; Millward MJ; Segal A; Nowak AK
Lung Cancer; 2015 Oct; 90(1):55-60. PubMed ID: 26259878
[TBL] [Abstract][Full Text] [Related]
55. An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma.
Belin LJ; Ady JW; Lewis C; Marano D; Gholami S; Mojica K; Eveno C; Longo V; Zanzonico PB; Chen NG; Szalay AA; Fong Y
Surgery; 2013 Sep; 154(3):486-95. PubMed ID: 23890748
[TBL] [Abstract][Full Text] [Related]
56. Diffuse malignant pleural mesothelioma: Part I. An overview of diagnosis, staging, and treatment options.
Brueggen C; Cordes ME
Clin J Oncol Nurs; 2003; 7(4):431-7. PubMed ID: 12929277
[TBL] [Abstract][Full Text] [Related]
57. Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: an evidence-based benchmark for cancer care.
Kao SC; van Zandwijk N; Clarke S; Vardy J; Lumba S; Tognela A; Ng W
Asia Pac J Clin Oncol; 2015 Mar; 11(1):85-92. PubMed ID: 25382807
[TBL] [Abstract][Full Text] [Related]
58. [Radiologic diagnosis in malignant pleural mesothelioma].
Gavelli G; Zompatori M; Bernasconi A; Galleri C; Canini R
Radiol Med; 1984 Nov; 70(11):830-6. PubMed ID: 6543973
[TBL] [Abstract][Full Text] [Related]
59. Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans.
Liu F; Zhao B; Krug LM; Ishill NM; Lim RC; Guo P; Gorski M; Flores R; Moskowitz CS; Rusch VW; Schwartz LH
J Thorac Oncol; 2010 Jun; 5(6):879-84. PubMed ID: 20421814
[TBL] [Abstract][Full Text] [Related]
60. Is the patient with mesothelioma without hope?
Maat AP; Cornelissen R; Bogers AJ; Takkenberg JJ
Future Oncol; 2015; 11(24 Suppl):11-4. PubMed ID: 26638916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
